Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Table 4

Clinical outcome.

	Cabazitaxel		Mitoxantrone
OS (months)	15.1		12.7	𝑃<0.0001
Median followup (months)	12.8			HR 0.70 (0.59–0.83)
PFS (months)	2.8		1.4	𝑃<0.0001
PSA progression (months)	6.4		3.1	𝑃=0.001
PSA response rate (%)	39.2		17.8	𝑃=0.0002
ORR (%)	14.4		4.4	𝑃=0.0005
	Abiraterone		Placebo
OS (months)	14.8		10.9	𝑃<0.001
Median followup (months)	12.8			HR 0.65 (0.54–0.77)
PFS (months)	5.6		3.6	𝑃<0.001
PSA progression (months)	10.2		6.6	𝑃<0.001
PSA response rate (%)	29		6	𝑃<0.001
ORR (%)	14		2.8	𝑃<0.001
	Enzalutamide		Placebo
OS (months)	18.4		13.6	𝑃<0.001
Median followup (months)	14.4			HR 0.63 (0.53–0.75)
PFS (months)	8.3		2.9	𝑃<0.001
PSA progression (months)	8.3		3	𝑃<0.001
PSA response rate (%)	54		2	𝑃<0.001
ORR (%)	29		4	𝑃<0.001